Advertisement

Advances in Therapy

, Volume 30, Issue 10, pp 933–944 | Cite as

Budget Impact Analysis of a Fixed-Dose Combination of Fluticasone Propionate and Formoterol Fumarate (FP/FORM) in a Pressurized Metered-Dose Inhaler (pMDI) for Asthma

  • William DunlopEmail author
  • Louise Heron
  • Georgia Fox
  • Maire Greaney
Original Research

Abstract

Introduction

The economic burden of asthma on the UK National Health Service (NHS) is the largest among allergic diseases. Current asthma guidelines recommend adding a long acting β2-agonist (LABA) to a low-dose inhaled corticosteroid (ICS) in patients who are on ICS monotherapy and have uncontrolled asthma. The fixed-dose combination of fluticasone propionate and salmeterol xinafoate (FP/SAL), available in a pressurized metered-dose inhaler (pMDI) device, is the most commonly prescribed ICS/LABA combination. An additional fixed-dose combination of fluticasone propionate and formoterol fumarate (FP/FORM) in pMDI is now available. In a 12-week non-inferiority study, FP/FORM demonstrated comparable efficacy to FP/SAL. The present analysis estimates the annual budget impact for the UK NHS using FP/FORM as an alternative to FP/SAL.

Methods

Current pMDI prescribing data were from a real-world UK patient database (Cegedim Strategic Data). Annual costs to the NHS for drug acquisition, administration, and monitoring were estimated for FP/FORM and FP/SAL and used to assess the potential budget impact for the NHS for the use of FP/FORM instead of FP/SAL. Varying rates of uptake, adherence, adverse event-related costs, and resource use associated with switching treatment were assessed in scenario analyses.

Results

Assuming similar levels of ICS use with both regimens, annual drug acquisition costs per person were lower with FP/FORM (£412) than with FP/SAL (£509). The difference in acquisition costs and otherwise comparable input costs between the treatments, results in potential annual savings of £15,110,279 to the NHS, assuming uptake of FP/FORM over FP/SAL in 50% of existing patients. The introduction of FP/FORM results in cost savings for the NHS in all of the assessed scenario analyses.

Conclusions

The comparable efficacy and lower acquisition costs of FP/FORM compared with FP/SAL make it a cost-saving option for the UK NHS for the treatment of asthma patients requiring combination maintenance therapy using a pMDI.

Keywords

Asthma Budget Cost savings Fluticasone propionate Formoterol fumarate Pressurized metered-dose inhaler Respiratory 

Notes

Acknowledgments

Sponsorship and article processing charges for this study were funded by Mundipharma International Ltd, United Kingdom. Adelphi Values Ltd received funding from Mundipharma International Ltd to support this research. Mr. Dunlop is the guarantor for this article, and takes responsibility for the integrity of the work as a whole.

Conflict of interest

William Dunlop is an employee of Mundipharma International Ltd, United Kingdom. Louise Heron is an employee of Adelphi Values Ltd, UK. Georgia Fox is an employee of Adelphi Values Ltd, UK. Maire Greaney is an employee of Adelphi Values Ltd, UK. The authors do not report any conflict of interest with regards to the contents of this study other than those stated.

Compliance with ethics

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. 1.
    Asthma UK. Key facts and statistics. 2012. http://www.asthma.org.uk/news-centre/facts-for-journalists. Accessed 24 Jan 2013.
  2. 2.
    Gupta R, Sheikh A, Strachan DP, Anderson HR. Burden of allergic disease in the UK: secondary analyses of national databases. Clin Exp Allergy. 2004;34:520–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Simpson CR, Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients. J R Soc Med. 2010;103:98–106.PubMedCrossRefGoogle Scholar
  4. 4.
    NHS Improvement—Lung: National Improvement Projects. Improving adult asthma care: emerging learning from the national improvement projects. 2012 Leicester, UK. http://www.improvement.nhs.uk/documents/asthmaimprovement.pdf. Accessed 24 Jan 2013.
  5. 5.
    Asthma UK. Wish you were here? UK report. 2008. http://asthmaserver.umbrellainc.co.uk/media/141035/wish_you_were_here__-_england_report.pdf. Accessed 24 Jan 2013.
  6. 6.
    Demoly P, Gueron B, Annunziata K, Adamek L, Walters RD. Update on asthma control in five European countries: results of a 2008 survey. Eur Respir Rev. 2010;19:150–7.PubMedCrossRefGoogle Scholar
  7. 7.
    British Thoracic Society/Scottish Intercollegiate Guidelines Network. British Guideline on the management of asthma. http://www.sign.ac.uk/pdf/qrg101.pdf. Accessed 24 Jan 2013.
  8. 8.
    Global strategy for asthma management and prevention. 2012. http://www.ginasthma.org/local/uploads/files/GINA_Report_March13.pdf. Accessed 24 Jan 2013.
  9. 9.
    Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000;320:1368–73.PubMedCrossRefGoogle Scholar
  10. 10.
    O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Criti Care Med. 2001;164:1392–7.CrossRefGoogle Scholar
  11. 11.
    Seale JP, Jenkins C, Wood-Baker R, Neville AM. Benefits of fixed-dose combination therapy with inhaled corticosteroids and long-acting bronchodilators as initial maintenance therapy in the management of asthma. Respirology. 2009;14:224–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Murphy AC, Proeschal A, Brightling CE, et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax. 2012;67:751–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Marceau C, Lemière C, Berbiche D, Perreault S, Blais L. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin immunol. 2006;118:574–81.PubMedCrossRefGoogle Scholar
  14. 14.
    Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, Bousquet J. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med. 2009;103:41–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM, ICAT SE study group. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007;62:1182–8.PubMedCrossRefGoogle Scholar
  16. 16.
    McKeage K, Keam S. Salmeterol/fluticasone propionate: a review of its use in asthma. Drugs. 2009;69:1799–828.PubMedCrossRefGoogle Scholar
  17. 17.
    CSD Patient Data. Cegedim Strategic Data UK Ltd. 2012.Google Scholar
  18. 18.
  19. 19.
    British National Formularity (BNF). 2013. http://www.bnf.org/bnf/index.htm. Accessed 28 May 2013.
  20. 20.
    Bodzenta-Lukaszyk A, Dymek A, McAulay K, Mansikka H. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med. 2011;11:28.PubMedCrossRefGoogle Scholar
  21. 21.
    Bodzenta-Lukaszyk A, Pulka G, Dymek A, et al. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. Respir Med. 2011;105:674–82.PubMedCrossRefGoogle Scholar
  22. 22.
    Seretide 50, 125, 250 Evohaler summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/2914. Accessed 31 Aug 2013.
  23. 23.
    Global initiative for asthma (GINA). Pocket guide for asthma management and prevention. 2012. http://www.ginasthma.org/local/uploads/files/GINA_Pocket2013_May15.pdf. Accessed 24 June 2013.
  24. 24.
    European Medicines Agency. Augmentin summary of product characteristics. 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Augmentin_30/WC500090608.pdf. Accessed 31 Aug 2013.
  25. 25.
    Personal Social Services Research Unit (PSSRU). Unit costs of health and social care 2012. http://www.pssru.ac.uk. Accessed 24 June 2013.
  26. 26.
    NHS England. Proposed CCG configuration and member practices published. http://www.england.nhs.uk/2012/05/24/ccg-configuration. Accessed 31 May 2013.
  27. 27.
    Mansur AH, Kaiser K. Long-term safety and efficacy of fluticasone/formoterol combination therapy in asthma. J Aerosol Med Pulm Drug Deliv. 2013;26:190–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Nathan RA, D’Urzo A, Blazhko V, Kaiser K. Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial. BMC Pulm Med. 2012;12:67.PubMedCrossRefGoogle Scholar
  29. 29.
    Aalbers R, Brusselle G, McIver T, Grothe B, Bodzenta-Lukaszyk A. Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study. Adv Ther. 2012;29:958-69.Google Scholar
  30. 30.
    Murphy KR, Bender BG. Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy. 2009;2:63–72.PubMedCrossRefGoogle Scholar
  31. 31.
    Bender BG, Long A, Parasuraman B, Tran ZV. Factors influencing patient decisions about the use of asthma controller medication. Ann Allergy Asthma Immunol. 2007;98:322–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Scottish Medicines Consortium. Fluticasone/formoterol (Flutiform). 2012. http://www.scottishmedicines.org.uk/SMC_Advice/Advice/736_11_fluticasone_formoterol_mdi_inhaler_Flutiform/fluticasone_formoterol_Flutiform. Accessed 24 June 2013.
  33. 33.
    National Institute for Health and Clinical Excellence (NICE). Technology appraisal guidance 138. Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over. http://www.nice.org.uk/TA138. Accessed 24 Jan 2013.

Copyright information

© Springer Healthcare 2013

Authors and Affiliations

  • William Dunlop
    • 1
    Email author
  • Louise Heron
    • 2
  • Georgia Fox
    • 2
  • Maire Greaney
    • 2
  1. 1.Mundipharma International LimitedCambridgeUK
  2. 2.Adelphi ValuesBollingtonUK

Personalised recommendations